From September 8th to September 10th, the Huayi List · 2024 China Biomedical Technology Innovation Value List, jointly initiated by Yiyun Technology and the National Technology Transfer Eastern Center, was released and awarded at the Zhangjiang Science Hall. Novamab was listed in the TOP10 list of the most promising biopharmaceutical companies.

The list of biopharmaceuticals mainly focuses on domestic enterprises with innovative biopharmaceutical pipelines and relatively advancedresearch and development progress. Being listed as one of the Top 10 Most Promising Biopharma Companies highlights the high recognition of the industry for the research and development achievements of Novamab's innovative nanobody drugs. In the future, Novamab will actively promote clinical and ongoing projects, and build itself into a global leading innovative nanobody drug research and development enterprise focused on respiratory and autoimmune fields, providing patients with updated and better innovative drugs.

About Huayi List

The Huayi List · 2024 China Biomedical Technology Innovation Value List aims to discover innovative enterprises in the field of biomedicine that truly have industry appeal and influence. This list includes three series of evaluations: enterprise value list, financial institution list, and park list. Based on the quantitative growth evaluation standards of enterprises polished by Huayi Research Institute for many years, combined with basic processes such as questionnaire surveys, enterprise interviews, data analysis, and verification, the evaluation team standardizes and quantifies the dynamic data of biopharmaceutical shortlisted enterprises and institutions to select enterprises with significant industry value for the year, forming an objective third-party evaluation list in the industry.

About Novamab

Novamab is an innovative biopharmaceutical enterprise dedicated to the research and industrialization of nanobody drugs. The company was established in October 2017 and is located in the Shanghai International Medical Park. It has established a complete research and development, CMC, and pilot production platform and system, and is currently the only company in China with full process development capabilities for nanobody drugs. Novamab has built a 500L Pichia pastoris nanobody GMP pilot production workshop, filling the industry gap in this field, which is extremely scarce and competitive.

As of September 2024, Novamab has applied for more than 80 domestic and foreign invention patents and has been granted 31 patents. Novamab Biotechnology's R&D pipeline covers areas such as respiratory system, immunotherapy, ophthalmology, and oncology, and has currently obtained 4 clinical approvals. The LQ036 and LQ043H products under development by Novamab Biotechnology have overturned the existing treatment methods for respiratory diseases, both of which are the world's first inhaled nanobody drugs of their respective target. LQ036 has completed Phase I clinical trials in China and Australia, and is currently undergoing Phase II clinical trials in China. Phase I clinical trials have demonstrated excellent drug safety and biomarker efficacy. The LQ043H project has completed a clinical Ia study in China, demonstrating excellent safety and drug tolerance.